TRANSVAC: new vaccines faster

Welcome to TRANSVAC, a collaborative infrastructure project funded under the European Commission’s (EC) 7th Framework Programme (FP7). The project is the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC was designed in order to enhance European research and training and foster the seamless implementation of a permanent research infrastructure for early vaccine development in Europe.

In order to reach its ambitious goal, TRANSVAC carries out activities at various levels. On this website you can find out about how to benefit from TRANSVAC’s portfolio of activities, learn how to apply for access to the TRANSVAC’s high-quality Infrastructure Free Services and Paid Services, how to participate in the free Workshops on Animal Models or in the free Modular Course on Concepts on Vaccine Development. Finally, TRANSVAC looks to the future and is exploring the implementation of a road map towards a sustainable European vaccine development platform beyond TRANSVAC. This is done by the European Vaccine Development Stakeholder Working Groups.


11 December 2014

Malaria Vaccine Development in Europe Workshop

Ninety people registered for the workshop, which was held at Louise Centre, Avenue Louise 287, Brussels

EVI valued your participation and extends heartfelt thanks for your contribution.  We are sure you join EVI in looking forward to witnessing the benefits of the workshop throughout the scientific community.

A report will be available at a later date, alternatively an article is being considered

03 November 2014

SEmalvac consortium call for the monitoring of a phase I clinical trial

This call is for a suitable independent Clinical Research Assistant (CRA) or a Contract Research Organisation (CRO) for the monitoring of a phase I clinical in CNRFP, Burkina Faso.

24 October 2014

EVI support leads to scientific breakthrough

A letter was published in Nature on 17 August fully acknowledging EVI and the InnoMalVac project.  Access to the structure is now paving the way forward to design improved vaccines against RH5, as well as the other RH malaria proteins.